Radium-223 dichloride treatment for prostate cancer with bone metastases: A symptomatic outcome review of 12 months experience

被引：0
|
作者：
Lee, H. H. [1 ]
McAddy, N. C. [1 ]
O'Sullivan, P. [1 ]
Crawley, P. [1 ]
Beesley, S. [2 ]
Naji, M. [1 ]
机构：
[1] Maidstone & Tunbridge Wells NHS Trust, Nucl Med Dept, Maidstone, Kent, England
[2] Maidstone & TunbridgeWells NHS Trust, Dept Oncol, Maidstone, Kent, England
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2016年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPW18
引用
收藏
页码：S214 / S215
页数：2
相关论文
共 50 条
  • [31] Radium 223 dichloride for prostate cancer treatment
    Deshayes, Emmanuel
    Roumiguie, Mathieu
    Thibault, Constance
    Beuzeboc, Philippe
    Cachin, Florent
    Hennequin, Christophe
    Huglo, Damien
    Rozet, Francois
    Kassab-Chahmi, Diana
    Rebillard, Xavier
    Houede, Nadine
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2643 - 2651
  • [32] Radium-223 as an Approved Modality for Treatment of Bone Metastases
    Brito, Ana Emilia
    Etchebehere, Elba
    SEMINARS IN NUCLEAR MEDICINE, 2020, 50 (02) : 177 - 192
  • [33] Radium-223 in the treatment of metastatic prostate cancer
    Marques, I. A.
    Abrantes, A. M.
    Pires, A. S.
    Costa, G.
    Tavares-Silva, E.
    Botelho, M. F.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S47 - S47
  • [34] Completion of radium-223 dichloride treatment regimen for patients with castrate resistant prostate cancer
    Amin, Kanak
    Shrikanthan, Sankaran
    Richard, Full
    Neumann, Donald
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [35] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [36] Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety
    Nilsson, Sten
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (07) : 1127 - 1136
  • [37] Radium-223 dichloride in patients with castration-refractory prostate cancer
    Winter, B. M.
    von Rundstedt, F. -C.
    Grimm, M. -O.
    UROLOGE, 2017, 56 (11): : 1435 - 1439
  • [38] Initial post-approval clinical experience with Radium-223 dichloride in patients with prostate cancer
    Conti, Peter
    Challa, Sudha
    Jadvar, Hossein
    Pinski, Jacek
    Gross, Mitchell
    Dorff, Tanya
    Quinn, David
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [39] MICRODISTRIBUTION OF ALPHA PARTICLE EMITTING RADIUM-223 DICHLORIDE IN MODELS OF PROSTATE CANCER BONE METASTASIS
    Abou, Diane
    Ulmert, David
    Hobbs, Robert
    Riddle, Ryan
    Thorek, Daniel
    JOURNAL OF UROLOGY, 2015, 193 (04): : E551 - E551
  • [40] COST-EFFECTIVENESS OF RADIUM-223 DICHLORIDE (RADIUM-223) IN ALSYMPCA: A COST-EFFECTIVENESS ANALYSIS OF RADIUM-223+BEST STANDARD OF CARE (BSOC) COMPARED WITH PLACEBO plus BSOC IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATIC BONE METASTASES IN CANADA
    Henricks, P.
    Cislo, P.
    Zhan, L.
    Beaudet, A.
    Grabbi, E.
    Lloyd, A.
    Fleshner, N.
    Chin, W.
    VALUE IN HEALTH, 2015, 18 (03) : A202 - A202
12345